InformationInformation Center

Recombinant Anti-EGFR Monoclonal Antibody Injection (Panitumumab)

Recombinant Anti-EGFR Monoclonal Antibody Injection (Panitumumab)

On December 5, 2018, Hualan Genetic Engineering Co., Ltd. received the clinical approval document of "Recombinant Anti-EGFR Whole Human Monoclonal Antibody Injection (Panitumumab)" issued by the State Drug Administration, with the approval number of 2018L03211. According to the drug registration procedure, Hualan Genetic Engineering Co., Ltd will organize and implement clinical trials as soon as possible in accordance with the requirements of the national drug clinical trials after obtaining the approval documents for the above drug clinical trials, and will apply the product production approval documents and GMP certificate after completing the clinical trials. Indication of Recombinant Anti-EGFR Monoclonal Antibody Injection (Panitumumab): Treatment of metastatic colorectal after cancerchemotherapy failure, esophageal cancer, prostate cancer.

Hualan | Hualan Biological


TAG:  Panitumumab, Hualan Bio China, Plasma Products, Vaccine, Anti-EGFR Monoclonal Antibody